Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eculizumab fails to inhibit generation of C5a in vivo

27 Nov 2014

Abstract excerpt

To the editor: Eculizumab is a monoclonal antibody (mAb) reputed to block C5 by preventing enzymatic generation of active components C5a and C5b.[1][1] C5a is a proinflammatory mediator whereas C5b combines with C6, C7, C8, and C9 to form the membrane attack complex C5b-9, which contributes to

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine and Purinergic Signaling
Share to Complement system in diseases
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25431478
DOI: 10.1182/blood-2014-07-589366

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eculizumab fails to inhibit generation of C5a in vivoPMID 25431478Read ↗

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivoSemantic proximity Read ↗

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panaceaSemantic proximity Read ↗

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19Semantic proximity Read ↗

The anaphylatoxin C5a: Structure, function, signaling, physiology, disease, and therapeuticsSemantic proximity Read ↗

With complements: C3 inhibition in the clinicSemantic proximity Read ↗

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.Semantic proximity Read ↗

The impact of eculizumab on routine complement assaysSemantic proximity Read ↗

[Genetic variants in C5 and poor response to eculizumab].Semantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Genetic Variants in C5 and Poor Response to EculizumabSemantic proximity Read ↗

A study of the molecular pharmacological properties of C5a and C5a des Arg : defining their biased agonist profile and contrasting biological functionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.